Related Experiment Video
Updated: May 29, 2026
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Autologous bone marrow cells and ischemic cardiomyopathy
Jerome Roncalli1, Patricia Lemarchand
1INSERM, UMR915, l'Institut du Thorax, Université de Nantes, UFR médecine CHU Nantes, Nantes, France. roncalli.j@chu-toulouse.fr
Insights
Intramyocardial stem cell injections improved heart function and reduced scar size in patients with ischemic cardiomyopathy. This regenerative medicine approach showed promising results for cardiac repair one year post-procedure.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Ischemic cardiomyopathy often leads to impaired cardiac function and adverse remodeling.
- Adult stem and progenitor cells are being investigated for their potential in cardiac repair after myocardial infarction.
- Previous studies in animal models showed that intramyocardial stem cell injections can induce reverse remodeling.
Discussion:
- The study evaluated transcatheter intramyocardial injections of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in patients with ischemic cardiomyopathy.
- The procedure was well-tolerated, with no serious adverse events reported.
- Cardiac MRI at one year revealed significant improvements in left ventricular function and reverse remodeling.
Key Insights:
- Transcatheter intramyocardial stem cell injection improved regional contractility in chronic myocardial scars.
- Patients showed a decrease in end-diastolic volume and infarct size, indicating reverse remodeling.
- Improved regional function predicted subsequent beneficial remodeling of the left ventricle.
Outlook:
- The findings suggest that stem cell therapy is a promising strategy for treating ischemic cardiomyopathy.
- Further clinical trials are warranted to optimize delivery methods and cell types for enhanced cardiac regeneration.
- This approach holds potential for improving long-term outcomes in patients with heart failure due to ischemic heart disease.
Abstract:
Evaluation of: Williams AR, Trachtenberg B, Velazquez DL et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ. Res. 108, 792-796 (2011). Transcatheter, intramyocardial injections of bone marrow-derived cells produce reverse remodeling in large animal models of ischemic cardiomyopathy. A variety of adult stem and progenitor cells from different sources have already been examined for their potential to promote cardiac repair and regeneration after myocardial infarction. This article reviews a recent study by Williams et al. who test the hypothesis that transcatheter, intramyocardial injections of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in left ventricular scar and border zone improve regional contractility of a chronic myocardial scar and that these changes predict subsequent reverse remodeling. All patients tolerated the procedure with no serious adverse events. At 1 year, cardiac MRI demonstrated a decrease in end diastolic volume, a trend toward decreased end systolic volume, decreased infarct size and improved regional left ventricular function. This article focuses on the findings and limitations of the study and provides an insight for future promising clinical trials.
Related Concept Videos
01:21Myocarditis I: Introduction
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...